Skip to main content
Fig. 6 | Cardiovascular Diabetology

Fig. 6

From: Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Fig. 6

Proportion of patients with reduced kidney function at baseline (eGFR < 60 mL/min/1.73 m2) in CARMELINA® compared to previously reported CV outcome trials of non-insulin glucose-lowering drugs for T2D. *eGFR < 50 mL/min/1.73 m2. CV cardiovascular, eGFR estimated glomerular filtration rate, QW once weekly, T2D type 2 diabetes

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840